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Abstract
Background: GLI pathogenesis-related 1 (GLIPR1) was originally identified in glioblastomas and its expression was
also found to be down-regulated in prostate cancer. Functional studies revealed both growth suppression and
proapoptotic activities for GLIPR1 in multiple cancer cell lines. GLIPR1’s role in lung cancer has not been
investigated. Protein arginine methyltransferase 5 (PRMT5) is a protein arginine methyltransferase and forms a
stoichiometric complex with the WD repeat domain 77 (WDR77) protein. Both PRMT5 and WDR77 are essential for
growth of lung epithelial and cancer cells. But additional gene products that interact genetically or biochemichally
with PRMT5 and WDR77 in the control of lung cancer cell growth are not characterized.
Methods: DNA microarray and immunostaining were used to detect GLIPR1 expression during lung development
and lung tumorigenesis. GLIPR1 expression was also analyzed in the TCGA lung cancer cohort. The consequence of
GLIPR1 on growth of lung cancer cells in the tissue culture and lung tumor xenografts in the nude mice was
observed.
Results: We found that GLIPR1 expression is negatively associated with PRMT5/WDR77. GLIPR1 is absent in growing
epithelial cells at the early stages of mouse lung development and highly expressed in the adult lung. Expression of
GLIPR1 was down-regulated during lung tumorigenesis and its expression suppressed growth of lung cancer cells
in the tissue culture and lung tumor xenografts in mice. GLIPR1 regulates lung cancer growth through the V-Erb-B
avian erythroblastic leukemia viral oncogene homolog 3 (ErbB3).
Conclusions: This study reveals a novel pathway that PRMT5/WDR77 regulates GLIPR1 expression to control lung
cancer cell growth and GLIPR1 as a potential therapeutic agent for lung cancer.
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Background
GLI pathogenesis-related 1 (GLIPR1) is similar to both
the pathogenesis-related protein superfamily and the
cysteine-rich secretory protein family [1–4]. It is also re-
ferred as the related to testes-specific, vespid, and patho-
genesis protein 1 (RTVP-1), originally identified in
human glioblastomas [2, 3]. GLIPR1 is highly expressed
in gliomas and astrocytic brain malignancies, and its ex-
pression level is correlated with the degree of malig-
nancy of astrocytic tumors [2, 3, 5]. GLIPR1
overexpression increased cell proliferation, survival, in-
vasion, migration and anchorage-independent growth of
glioma cells [5]. GLIPR1 was variably expressed in meta-
static melanoma and elevated GLIPR1 levels were corre-
lated with increased invasive potential [6]. Elevated
GLIPR1 expression was also detected in Wilms tumors
[7]. In contrast, GLIPR1 expression was down-regulated
in prostate cancer and functions as a tumor-suppressor
gene in prostate cancer [8, 9]. Overexpression of GLIPR1
induced apoptosis [10] and/or mitotic catastrophe (MC)
in prostate cancer cells [11]. Adenoviral vector-mediated
GLIPR1 therapy in an immunocompetent orthotopic
prostate mouse model showed significantly reduced
tumor-associated angiogenesis [12]. A novel GLIPR1-
modified tumor cell vaccine also showed significant anti-
tumor activity in a mouse model of recurrent prostate
cancer [13]. Furthermore, a phase I clinical trial of neo-
adjuvant intraprostatic injection of GLIPR1 delivered by
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adenoviral vector for localized and intermediate and
high-risk prostate cancer before radical prostatectomy
showed antitumor activity and favorable modulation of
blood-based biomarkers of immune stimulation [14].
V-Erb-B avian erythroblastic leukemia viral oncogene
homologs (ErbBs) belong to the family of tyrosine kinase
receptors, which containing four members (ErbB1/
EGFR, ErbB2/Her2, ErbB3/Her3, and ErbB4) [15, 16].
Insufficient ErbB signaling in humans is associated with
the development of neurodegenerative diseases, while
excessive ErbB signaling is associated with the develop-
ment of a wide variety of types of solid tumors [17, 18].
These cell surface receptors are comprised of a compos-
ite extracellular domain which contains a well defined
ligand-binding site, a single pass transmembrane do-
main, and an intracellular domain with tyrosine kinase
activity [17, 19]. Ligand binding induces homo or het-
erodimerization between ErbB receptors, leading to acti-
vation of their tyrosine kinase activity, and activation of
multiple downstream pathways [20, 21]. It was reported
that ERBB3 played a major role in division, survival, mo-
tility, migration, and invasiveness of lung cancer cells
[22, 23] and high ERBB3 expression was also associated
with poor prognosis in lung cancer patients [24–26].
Protein arginine methyltransferase 5 (PRMT5) is a
type II protein arginine methyltransferase that catalyzes
the symmetrical dimethylation of arginine residues
within target proteins and has been implicated in diverse
cellular and biological processes [27]. PRMT5 forms a
stoichiometric complex with the WD repeat domain 77
(WDR77/MEP50/WD45/p44) in various cells [28–30].
PRMT5 and WDR77 proteins in the cytoplasm are re-
quired for proliferation of prostate epithelial and pros-
tate cancer cells [31–36]. In contrast, in the nucleus,
they function with the androgen receptor to drive pros-
tate epithelial cell differentiation and function [33, 34,
37]. More recently, we found that WDR77 is highly
expressed in the lung at the early development stage
when cells are rapidly proliferating and its expression is
diminished in adult lung when cells are fully differenti-
ated [31]. Loss of WDR77 expression led to growth ar-
rest of lung epithelial cells at the G1 cell cycle phase.
More important, PRMT5 and WDR77 were re-activated
in lung cancers and the small hairpin RNA (shRNA)-me-
diated silencing of PRMT5 or WDR77 expression
strongly inhibited growth of lung cancer cells in the tis-
sue culture and abolished growth of lung tumor xeno-
grafts in the nude mouse [31, 32]. These results reveal a
novel role of PRMT5 and WDR77 in growth of lung epi-
thelial cells as well as lung cancers.
In searching for genes that mediate PRMT5 and
WDR77 functions in lung cancer cells, we performed
DNA microarray analysis (GSE56757) with lung adeno-
carcinoma A549 cells expressing WDR77 or PRMT5
shRNA [32, 31] and found that the loss of WDR77 or
PRMT5 expression significantly up-regulated GLIPR1
expression. GLIPR1 expression was down-regulated dur-
ing lung tumorigenesis and re-expression of GLIPR1
inhibited proliferation of lung cancer cells and growth of
lung tumor xenografts. This study identifies GLIPR1 as a
tumor suppressor for lung cancers.
Results and discussion
GLIPR1 expression was suppressed by WDR77 in lung
cancer cells
Silencing expression of WDR77 or PRMT5 dramatically
inhibited proliferation of lung (A549 and PC14) and
prostate (PC3 and LNCaP) cancer cells [32, 36]. To in-
vestigate potential molecular mechanisms through which
WDR77/PRMT5 functions, we performed DNA micro-
array expression profiling and found that GLIPR1 gene
expression was up-regulated by 7-fold in WDR77-
silenced A549 cells (Fig. 1a) and 11-fold in PRMT5-
silenced A549 cells (GSE56757), which was confirmed
by an RT-PCR analysis (Fig. 1a). GLIPR1 protein levels
were also significantly (9.4-fold) higher in WDR77-
silenced A549 cells comparing to the control A549 cells
(Fig. 1b, lane 2 versus lane 1). The anti-GLIPR1 antibody
detected two protein bands, the upper one represents
the N-glycosylated form of GLIPR1 [46]. These results
suggest that WDR77 suppresses GLIPR1 expression in
lung cancer A549 cells. We further tested GLIPR1 ex-
pression in the other WDR77-silenced lung (PC14) and
prostate (LNCaP and PC3) cancer cells. Both mRNA
(Fig. 1c) and protein (Fig. 1d) levels of GLIPR1 were
higher in WDR77 shRNA-expressing LNCaP and PC14
cells compared with non-target (NT) shRNA-expressing
LNCaP and PC14 cells (Fig. 1d, lane 2 versus lane 1, lane
4 versus lane 3). However, silencing WDR77 expression
did not enhance GLIPR1 expression in PC3 cells (Fig. 1c;
Fig. 1d, lane 6 versus lane 5). We noticed that GLIPR1
protein levels are low in A549, PC14 and LNCaP cells
but high in PC3 and glioma U87 cells (Fig. 1b, lane 1,
Fig. 1d, lanes 1, 3, 5; Additional file 1: Figure S1). Con-
sistent with these observations, we also found that
GLIPR1 mRNA levels in PC3 cells are also much higher
than that in A549, PC14 and LNCaP cells. These results
indicate that GLIPR1 expression is inversely associated
with WDR77 in A549, PC14 and LNCaP cells and such
association is absent in PC3 cells. Furthermore, the
DNA microarray analysis (GDS1688) indicates that
GLIPR1 expression in all of the tested lung cancer cell
lines except PC-6 is lower than that in A549 cells (Add-
itional file 2: Figure S2), which is associated with high
expression of WDR77 in these cell lines (Additional file
3: Figure S3).
Immunostaining of mouse lung tissues with the anti-
GLIPR1 antibody was performed to detect GLIPR1
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expression. At the age of 9 days after birth, GLIPR1 is
very low in the mouse lung epithelial and alveolar cells
(Fig. 2a). At the age of 180 days, high GLIPR1 levels in
the cytoplasm of both epithelial and alveolar cells were
detected (Fig. 2b). Western blot analysis confirmed this
observation (Fig. 2a, insert). In our previous study, we
reported that WDR77 was highly expressed in the lung
of mouse at the age of 1–14 days, while absent in the
lung of mouse at the age of 120–390 days. Thus,
GLIPR1 expression is inversely correlated with WDR77
expression during the lung development. Consistent
with this conclusion, the DNA microarray analysis
(GDS3950) demonstrated that GLIPR1 expression is also
inversely correlated with WDR77 expression during the
mouse lung development from the embryonic day 12 to
the postnatal day 30 (Additional file 4: Figure S4).
We then examined GLIPR1 expression in lung cancer
samples derived from 35 patients. GLIPR1 was highly
expressed in benign (Fig. 3ai, indicated by red arrows)
and normal (Fig. 3bi) lung epithelial cells. In the lung
hyperplasia region (Fig. 3ai, circled by red line), some
cells lost GLIPR1 expression (indicated by blue arrows)
but the others remain GLIPR1-staining positive with the
decreased GLIPR1 protein levels (indicated by red ar-
rows). In contrast, WDR77 expression is absent in nor-
mal lung epithelial (Fig. 3aii, insert) and alveolar
(Fig. 3aiii, insert) cells but robust and ubiquitous in lung
hyperplasia derived from lung epithelial cells (Fig. 3aii,
circled by the red line) or from alveolar cells (Fig. 3aiii,
circled by the red line). The expression of WDR77 is
also ubiquitous in lung cancers (Fig. 3bvi). In contrast,
GLIPR1 expression is variable in all 35 lung cancer sam-
ples (Three cases of lung cancers are shown in Fig. 3bii/
iii/iv.) with some lung cancer cells expressing GLIPR1 at
the decreased protein levels (Fig. 3bii/iii/iv, Some are in-
dicated by red arrows but others not.). Consistent with
this observation, GLIPR1 expression is also decreased in
lung cancers [cohort: the Cancer Genome Atlas (TGCA)
lung cancer, n = 1,127] (Fig. 3bv). It was also shown that





































































Fig. 1 GLIPR1 expression was suppressed by WDR77 in lung and prostate cancer cells. a DNA microarray and RT-RCR analysis of GLIPR1 mRNA expression
in A549 cells. Fold-increase = GLIPR1 mRNA signals of cells expressing WDR77 shRNA/GLIPR1 signals of cells expressing NT shRNA. bWestern Blot analysis
of whole-cell lysates derived from A549 cells expressing NT shRNA (lane 1) or WDR77 shRNA (lane 2) with anti-WDR77, anti-GLIPR1 or anti-actin antibodies
as indicated. c RT-RCR analysis of GLIPR1 mRNA expression in LNCaP, PC14, or PC3 cells. Fold-increase = GLIPR1 mRNA signals of cells expressing WDR77
shRNA/GLIPR1 signals of cells expressing NT shRNA. d Western Blot analysis of whole-cell lysates derived from PC14, LNCaP, or PC3 cells expressing NT
shRNA (lane 1, 3, 5) or WDR77 shRNA (lane 2, 4, 6) with anti-WDR77, -CLIPR1, or -actin antibody as indicated
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towards mutual exclusivity in 230 lung cancers [38].
Thus, GLIPR1 expression is down-regulated and in-
versely correlated with WDR77 expression during lung
tumorigenesis. Consistent with this conclusion, gene ex-
pression microarray analysis (GDS4794) demonstrated
that GLIPR1 expression is down-regulated in 23 small
cell lung cancers (SCLC) (Additional file 5: Figure S5).
WDR77 regulates GLIPR1 expression through the TGFβ
signaling
In our previous study, we found that loss of WDR77 ex-
pression activated the TGFβ signaling pathway through up-
regulation of TGFβ2 and TGFβII expression [39]. To test
whether the TGFβ signaling mediates the WDR77-
regulated GLIPR1 expression, we first treated A549 cells
with the recombinant human TGFβ2. TGFβ2 enhanced
GLIPR1 expression by 2.1-fold (Fig. 4a, lane 2 versus lane
1). We then treated A549 cells that express WDR77 or NT
shRNA with SB431542, a TGFβ receptor inhibitor. Silen-
cing WDR77 induced GLIPR1 protein expression by 14-
fold (Fig. 4b, lane 2 versus lane 1), which was greatly sup-
pressed by SB431542 (lane 4 versus lane 3). These results
suggest that the TGFβ signaling pathway participates in
GLIPR1 up regulation upon WDR77 knockdown. Our
Fig. 2 GLIPR1 expression is up-regulated during mouse lung development. Lung tissues obtained from mice at the age of 9 (a) or 180 (b) days were
immunostained using the anti-GLIPR1 antibody. GLIPR1-expressing cells are stained in brown. The insert shows Western blot analysis of protein extracts
made from the lungs of mice at the age of 9 (lane 1) or 180 (lane 2) days using the anti-GLIPR1 antibody
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Fig. 3 (See legend on next page.)
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current efforts are focused on how WDR77 suppresses the
TGFβ signaling which in turn regulates GLIPR1 gene
expression.
GLIPR1 was identified as a TP53 target gene [40]. Si-
lencing WDR77 expression slightly (2-fold) decreased
TP53 protein level in LNCaP cells (Additional file 6:
Figure S6A). We constructed a TP53 luciferase reporter
(pGL3-4xPBE-E4-luc), which contains four copies of the
TP53 DNA-binding sequence (PBE) fused to the E4 core
promoter and luciferase gene. This reporter was transi-
ently transfected into LNCaP cells that expressed NT or
WDR77 shRNA and the promoter activity was deter-
mined by measuring the luciferase activity. Silencing
WDR77 also slightly decreased the p53-reporter activity
(Additional file 6: Figure S6B). Thus, WDR77 regulates
GLIPR1 gene expression not through p53.
GLIPR1 inhibits cell proliferation and arrests cell cycle at
G1 and G2 phases
We showed previously that silencing WDR77 expression
significantly decreased proliferation of prostate and lung
cancer cells [39, 41]. We then investigated whether
GLIPR1 influences growth of lung cancer cells. A549
cells were infected with lentivirus expressing GLIPR1
protein. GLIPR1 protein levels were increased (up to
7.5-fold) in A549 cells in a lentiviral dosage-dependent
manner (Fig. 5a, lanes 2–4). GLIPR1 over expression re-
sulted in a significant inhibition of cell growth and the
cell growth rate is inversely correlated with GLIPR1 pro-
tein levels (Fig. 5b).
We then performed a BrdU incorporation assay to
measure the proliferation rate of control and GLIPR1-
expressing A549 cells. About 75 % control cells are
stained positively by the anti-BrdU antibody (Fig. 5c,
left-hand panel, in brown; Fig. 5d), indicating the major-
ity of control cells are proliferative. In contrast, only
about 5 % of GLIPR1-expressing cells stained positively
for BrdU. (Fig. 5c, right-hand panel, indicated by the
black arrow; Fig. 5d). Thus, GLIPR1 expression is nega-
tively correlated with cellular proliferation. Flow cytome-
try analysis revealed no significant difference in the
apoptosis rate (sub G cell population) between GLIPR1-
expressing and the control A549 cells (Additional file 7:
Figure S7), indicating that GLIPR1 expression did not
induce apoptosis in lung cancer cells. However, the pro-
portion of the GLIPR1-expressing cells in the G1- and
G2-phases of the cell cycle was significantly higher than
that in control cells (Additional file 7: Figure S7). Con-
versely, the proportion of GLIPR1 expressing cells found
in S-phase was lower than that in control A549 cells.
Thus, GLIPR1 inhibits cellular proliferation by arresting
cell cycle at G1 and G2 phases.
GLIPR1 down regulates ErbB2/3 expression
Our previously reported gene expression microarray ex-
periments demonstrated that silencing WDR77 or
PRMT5 down-regulated ERBB2/3 and FGFR3 gene ex-
pression (GSE56757) [33]. Western blotting analysis
showed that GLIPR1 expression also decreased expres-
sion of FGFR3, ERBB2, and ERBB3 proteins in A549
cells (Fig. 6a, lane 2 versus lane 1). RT-PCR analysis in-
dicated that this regulation was at the mRNA level
(Fig. 6b). Besides, the expression of FGFR1/2/4 was
down-regulated by GLIPR1 as well, which may also con-
tribute to GLIPR1’s suppressor function (Fig. 6b). It was
reported that GLIPR1 overexpression led to activation of
the c-Jun-NH2 kinase pathway in a TSU-Pr1-derived cell
line [42] and stimulated CK1α-mediated β-catenin and
c-Myc destruction in multiple prostate cancer cell lines
[10]. However, GLIPR1 expression did not alter c-Jun
and c-Myc protein levels in A549 cells (Fig. 6a, lane 2
versus lane 1). Similarly, we also expressed GLIPR1 in
prostate cancer LNCaP and PC3 cells (Fig. 6c) and com-
pared with control cells, GLIPR1 protein levels were in-
creased by 26.6- and 2-fold in GLIPR1-expressing
LNCaP (lanes 1 and 2) and PC3 (lanes 3 and 4) cells, re-
spectively (Fig. 6c). GLIPR1 expression decreased the
protein levels of ERBB2 and ERBB3, but did not alter
(See figure on previous page.)
Fig. 3 GLIPR1 expression is down-regulated during lung tumorigenesis. Immunostaining of GLIPR1 or WDR77 in normal lung tissues (a-ii, insert
panels; b-i), lung hyperplasia (a, surrounded by red lines), and lung cancer (b). GLIPR1 or WDR77-expressing cells are stained in brown. (b-v),
































Fig. 4 WDR77 regulates GLIPR1 expression through the TGFβ
signaling. a Western Blot analysis of whole-cell lysates derived from
A549 cells grown in the absence or presence of the recombinant
human TGFβ2 (10 ng/ml, Biolegend) (lane 2) for 24 h. b Western Blot
analysis of whole cell extracts made from A549 cells expressing NT
shRNA treated with DMSO (lane 1) or SB431542 (10 μM) (lane 2) and
A549 cells expressing WDR77 shRNA treated with DMSO (lane 3) or
SB431542 (lane 4) for 24 h
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FGFR3 protein levels in LNCaP cells (Fig. 6c, lane 2 ver-
sus lane 1). In contrast, GLIPR1 expression did not alter
levels of any of these three proteins in PC3 cells (Fig. 6c,
lane 4 versus lane 3). GLIPR1 expression also inhibited
growth of LNCaP but not PC3 cells (Fig. 6d).
ERBB3 expression is also inversely correlated with
GLIPR1 expression in 230 lung cancer samples (Fig. 7a)
[38]. Ectopic expression of ERBB3 (Fig. 7b) partially re-
stored the cell growth inhibition induced by GLIPR1 ex-
pression in A549 cells (Fig. 7c). Thus, these results
indicate that ErbB3 may participate in cell growth inhib-
ition mediated by GLIPR1. However, ERBB3 expression
failed to fully restore the cell growth inhibition induced
by GLIPR1 expression. ERBB2 lacks ligand-binding abil-
ity, whereas ERBB3 is unique in that it does not have
any intrinsic kinase activity [43, 44]. ERBB2 and ERBB3
form the heterodimer and perform a central role in
maintenance and malignancy of lung cancers and other
cancers [24, 26, 45–47]. Combined blockade of ERBB2
and ERBB3 inhibited PI3K/Akt activity more effectively
than each inhibitor alone [45, 47]. It may be possible
that ERBB2 and ERBB3 should be co-expressed in order
to fully restored growth inhibition induced by GLIPR1.
It is possible that other signal pathways such as FGFR
also mediate growth-suppression function of GLIPR1.
GLIPR1 suppressed lung tumor growth in an orthotopic
mouse model
To determine the effects of GLIPR1 on lung cancer, we
observed the growth of orthotopic tumors in mice
formed from the control A549 cells or A549 cells ex-
pressing GLIPR1 (Fig. 8a). Large, macroscopically visible
tumors were found in the lungs of the mice injected
with the control A549 cells (Fig. 8b, panels i-v). How-
ever, only a small tumor was observed in the lung of one
mouse injected with GLIPR1-expressing A549 cells
Fig. 5 GLIPR1 inhibits cell proliferation. a Western blot analysis of whole-cell lysates derived from A549 cells infected with the control lentivirus
(lane 1) or with variable amounts (50, 100, or 200 μl) of lentivirus expressing GLIPR1 (lanes 2–4). b Growth curves of control A549 cells or A549
cells expressing different levels of GLIPR1. c A549 cells infected with control lentivirus or GLIPR1-expressing lentivirus were allowed to grow in the
presence of BrdU and immunostained with the anti-BrdU antibody (brown). The green arrow (left-hand panel) indicates the BrdU-negative staining
cell and the black arrows (right-hand panel) indicate the BrdU-positive staining cells. d Percentage of BrdU-positive cells in A549 cells infected with
control lentivirus or GLIPR1-expressing lentivirus. The results represent the means of three independent experiments ± the standard error of the
mean (SEM). *, P<0.05; **, P<0.01; ***, P<0.001
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(Fig. 8b, pane viii). No tumors were detected in the lungs
of the other 4 mice injected with GLIPR1-expressing
A549 cells (Fig. 8b, panels vi, vii, ix, x). The average
tumor size (tumor area mean) in the mice injected with
the control A549 cells was 15-fold higher than that of
the lung tumors in mice injected with GLIPR1-
expressing A549 cells (Fig. 8c). These results indicate
that GLIPR1 functions as a tumor suppressor in lung
tumors.
GLIPR1 performs dual functions in PC3 cells
GLIPR1 protein levels in PC3 are much higher than that
in A549, PC14, and LNCaP cells (Additional file 1:
Figure S1) and 2-fold increase in GLIPR1 protein levels
did not affect growth of PC3 cells (Fig. 6c, d). However,
previous studies showed that GLIPR1 overexpression in-
duced apoptosis in PC3 cells [40]. By carefully examining
GLIPR1 protein levels, we found that the adenovirus-
mediated expression in the previous study [40] yielded
much higher GLIPR1 protein levels than the lentivirus-
mediated GLIPR1 expression used here. We constructed
another GLIPR1-expressing lentivirus by inserting three
deoxynucleotides (ACC) immediately before the transla-
tion initiation codon (ATG) of GLIPR1 cDNA, which sig-
nificantly enhanced the translation efficiency [48, 49].
Indeed, GLIPR1 protein levels in PC3 cell could be in-
creased up to 6.3-fold (Fig. 9a, lane 3 versus lane 1). High
levels of GLIPR1 significantly inhibited PC3 cell growth
Fig. 6 GLIPR1 down regulates expression of ERBB2/3 genes. a Western blot analysis of whole-cell lysates derived from control A549 cells (lane 1)
or GLIPR1-expressing A549 cells (lane 2) with antibodies as indicated. b RT-RCR analysis of ERBB3, FGFR1, FGFR2, FGFR3, and FGFR4 expression.
Relative mRNA level = mRNA in A549 cells expressing GLIPR1/mRNA in the control A549 cells. c Western blot analysis of whole-cell lysates derived
from control LNCaP cells (lane 1), GLIPR1-expressing LNCaP cells (lane 2), control PC3 cells (lane 3), or GLIPR1-expressing PC3 cells (lane 4) with
antibodies as indicated. d Growth curves of control LNCaP cells, GLIPR1-expressing LNCaP cells, control PC3 cells or GLIPR1-expressing PC3 cells
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(Fig. 9b). Flow cytometry cell cycle analysis confirmed that
high GLIPR1 expression indeed induced apoptosis in
about 50 % cells (Fig. 9c), which is similar to the published
results [40]. In addition, high GLIPR1 expression also sig-
nificantly decreased the cell population found in S phase
(Fig. 9c).
It was reported that GLIPR1 was highly expressed in
glioma and functioned as an oncogene [2, 5]. We then
tested whether the endogenous GLIPR1 protein per-
forms any function in PC3 cells. PC3 cells were infected
with lentivirus expressing the NT or GLIPR1 shRNA.
GLIPR1 shRNA significantly decreased GLIPR1 protein
expression in PC3 (Fig. 9d, lanes 2–5 versus lane 1). Si-
lencing GLIPR1 expression inhibited PC3 cell growth in
a dosage dependent manner (Fig. 9e). This result is con-
sistent with the published observations in glioma cells
[2, 5]. Therefore, GLIPR1 expression is required for PC3
cell growth, while overexpression of GLIPR1 at much
higher levels inhibits PC3 cell growth by inducing cell
apoptosis. These results are consistent with the observed
role of GLIPR1 in glioma and Wilms tumors [20, 22]. A
possible explanation for the conflicting cancer-related
functions of GLIPR1 is that it may form complexes with




































Fig. 7 a ErbB3 expression is inversely correlated with GLIPR1 expression in lung cancers. mRNA co-expression of GLIPR1 versus ErbB3 in 230 lung
cancer samples. Data was obtained from the Cancer Genome Atlas (TCGA, lung cancer, 2014) and analyzed using cBioPortal (www.cbioportal.org).
b, c Ectopic expression of ErbB3 partially restores cell growth inhibition by GLIPR1. b Western blot analysis of whole-cell lysates derived from con-
trol A549 cells (lane 1) or A549 cells expressing GLIPR1 or GLIPR1 plus ERBB3. c Growth of A549 cells expressing GLIPR1 or GLIPR1 plus ERBB3. **,
P<0.01; ***, P<0.001.
Sheng et al. Molecular Cancer  (2016) 15:25 Page 9 of 14
protein deleted of the N-glycosylation site [48] inhibited
cell growth as well as the wild-type GLIPR1 (Data not
shown), indicating that the N-glycosylation of GLIPR1
does not affect its function to suppress lung cancer cell
growth.
Conclusions
Silencing WDR77 or PRMT5 expression in lung cancer
A549 cells induced expression of GLPIR1 revealed by
DNA microarray (GSE56757) and RT-PCR analyses. Such
regulation also exists in other lung (PC14) and prostate
(LNCaP) cancer cells. GLIPR1 expression is inversely cor-
related with WDR77 during mouse lung development.
WDR77 and PRMT5 are ubiquitously re-expressed in
lung hyperplasia and cancer [31, 32] and conversely,
GLIPR1 expression is significantly down-regulated during
lung tumorigenesis. Thus, these results suggest the nega-
tive regulation of the GLIPR1 gene by WDR77.
Our mechanistic studies show that GLIPR1 inhibits
expression of ERBB2/3 in A549 and LNCaP cells.
Moreover, ERBB3 expression is inversely correlated with
GLIPR1 in 230 lung cancers [38]. Ectopic expression of
ERBB3 partially restores growth inhibition induced by
GLIPR1, suggesting that GLIPR1 inhibits lung cancer
cell growth through suppressing ERBB3.
Although GLIPR1 has been reported to possess tumor
suppressor activities in prostate cancer cells [40, 50], its
function in lung cancer have not yet been reported. We
found that GLIPR1 inhibited expression of ERBB2/3 and
proliferation of both lung cancer (A549, PC14) and
prostate cancer (LNCaP) cells. Thus, GLIPR1 may serve
as a novel therapeutic agent for lung cancer by using ei-
ther gene or protein delivery methods. Such methods
are currently under phase I clinical trial of prostate can-
cer treatment [13, 14].
Methods
RNA interference and gene expression profiling
The WDR77 and non-target (NT) small hairpin RNAs









































Fig. 8 GLIPR1 inhibited growth of lung tumor xenografts. a Western blot analysis of whole-cell lysates derived from control A549 cells (lane 1) or
GLIPR1-expressing A549 cells (lane 2) with anti-GLIPR1 (top) or anti-actin (bottom) antibody. b Lungs derived from mice injected with control
A549 cells (panels i-v) or A549 cells expressing GLIPR1 (panels vi-x). c Mean size of tumors in mouse lungs injected with the control A549 cells or
A549 cells expressing GLIPR1. Vertical bars indicate SEM. ***, P<0.001
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shRNA target sequence (5’-GGA CUA UGA CUU CAA-
GAC Udtdt-3’) was designed [51] and cloned into the lenti-
viral gene transfer vector pLVTHM. The DNA construct
was sequenced to determine the proper insertion. The
lentivirus production and cell infection were performed as
describe. The infected cells were then submitted for
growth assay and harvested for Western blot and real-
time PCR analyses. A gene expression profiling analysis
(GSE56757) was performed on A549 cells expressing
WDR77, PRMT5, or NT shRNA. The Cancer Genome
(TCGA) data of GLIPR1 expression in lung samples were
retrieved from https://genome-cancer.ucsc.edu/download/
public/xena/TCGA/TCGA.LUNG.sampleMap/HiSeqV2
and analyzed for significant expression differences using
RSEM [52].
Real-time PCR
Total RNAs were isolated from cultured cells using TRI-
zol reagent and reverse transcribed into cDNA using the
Reaction Ready First Strand cDNA Synthesis Kit (Super-
Array Bioscience Corp.). The cDNA products were
PCR-amplified with the RT2 Real-Time SYBR Green
PCR master mix (SuperArray Bioscience Corp.) and the
gene-specific primer sets (Additional file 8: Table S1) for
human GLIPR1, FGFR1, FGFR2, FGFR3, FGFR4, ErbB3,
and β-actin genes (Sigma) using a SmartCycler II (Ce-
pheid; 40 cycles of 30 s at 94 °C, 30 s at 55 °C and 30 s
at 72 °C). The SmartCycler software program (version
2.0C) was used to process and quantify raw data. The
2-ΔΔCT method was used to relatively quantify target
gene expression as described previously [53].
Fig. 9 Dual functions of GLIPR1 in PC3 cells. a Western blot analysis of whole-cell lysates derived from control PC3 cells (lane 1), PC3 cell infected
with low (lane 2) or high (lane 3) amounts of GLIPR1-expressing lentivirus. b Cell numbers 6 days after infected with control lentivirus or GLIPR1-
expressing lentivirus. c The cell-cycle distribution in control or high GLIPR1-expressing lentivirus infected PC3 cells by using flow cytometric ana-
lysis. d Western blot analysis of whole-cell lysates derived from PC3 cells expressing NT shRNA (lane 1) or GLIPR1 shRNA (lane 2–5) with anti-
GLIPR1 or anti-actin antibody. e Cell numbers 6 days after infected with NT shRNA-expressing or GLIPR1 shRNA expressing lentivirus. **, P<0.01;
***, P<0.001
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Western blot analysis
Protein extracts made from the cultured cells were sub-
jected to 10 % sodium dodecyl sulfate-polyacrylamide
gel electrophoresis and then transferred to Immobilon-P
membranes (Millipore). The blots were then probed for
2 h with primary antibodies at dilutions of 1:1,000 (anti-
WDR77), 1:1,000 (anti-FGFR3), 1:1,000 (anti-c-Myc,
Santa Cruz Biotechnology), 1:1,000 (anti-c-Jun, Santa
Cruz Biotechnology), or 1:5,000 (anti-β-actin, Sigma-
Aldrich) or overnight with primary antibody at dilutions
of 1:1,000 (anti-ErbB3), 1:1,000 (anti-ErbB2), or 1:1,000
(anti-GLIPR1). The blots were then incubated with a
horseradish peroxide-conjugated secondary antibody for
1.5 h. Immunoreactive proteins were detected using an
enhanced chemiluminescence detection system (GE
Healthcare) per the manufacturer’s instructions. Protein
concentrations were determined using the Bradford pro-
tein assay (Bio-Rad). The protein bands were scanned
using a densitometer, and the relative intensities were
quantified using the ImageJ software program (ImageJ64,
National Institutes of Health).
Lung samples and immunohistochemical staining
Lung tumor samples were obtained from patients with
lung cancer who underwent surgery at Tangdu Hospital
(Xi’an, China), and the study protocol was approved by
its institutional review board. The confidential informa-
tion of patients cannot be traced from lung tumor sam-
ples. BALB/c mice were purchased from the National
Cancer Institute and maintained in the Animal Facility
of Morehouse Medical School. Mouse lung tissues prep-
aration was performed as described previously. Mice
were handled in accordance with the guidelines pub-
lished in the National Institutes of Health Guide for the
Care and Use of Laboratory Animals. The Morehouse
Medical School’s Institutional Animal Care and Use
Committee approved all the experimental procedures
used for mice. Antigen retrieval and immunostaining
with anti-GLIPR1 (Abnova, 1:200) or -WDR77 (1:1,000)
antibody were performed as described [32]. Immuno-
staining without the primary antibody served as a nega-
tive control.
Cell culture, cell growth assay, and the treatment with
TGFβ2
A549 and PC14 cells were cultured in minimum essen-
tial medium (Cellgro) with 10 % (v/v) fetal bovine serum
(FBS) (HyClone), 2 % vitamins, 1 % L-glutamine, 1 %
non-essential amino acids, and 1 % sodium pyruvate.
PC3 and LNCaP cells were cultured in RPMI 1640
medium (Cellgro) with 10 % FBS. For the growth assay,
cells were plated on 24-well plates (2, 000 cells/well) and
counted every day for 7 days. For bromodeoxyuridine
(BrdU) (BD Biosciences) incorporation assay, cells (50–
70 % confluence) were plated on a Chamber slide (BD
falcon) and cultured in the presence of 10 μM BrdU for
4 h. The BrdU-positive cells were detected by immuno-
staining with the monoclonal anti-BrdU antibody (BD
Biosciences).
For the TGFβ2 treatment, A549 cells were seeded in
6-well plates in the growth medium. The fresh medium
containing 10 ng/ml recombinant human TGFβ2 (Biole-
gend) was added 24 h later. Cells were cultured for 24 h
in a CO2 incubator and were harvested for Western blot
analysis. A549 cells were first transfected with lentivirus
expressing non-target (NT)-shRNA or WDR77 shRNA
and 3 days post infection, the fresh medium containing
either 0.1 % DMSO or 10 μM SB431542 (Reagents Dir-
ect) was then added. Cells were harvested for Western
blot analysis 24 h later. Each experiment was performed
in triplicate.
Flow cytometry cell cycle analysis
Cells (50–60 % confluency) were harvested, washed with
phosphate-buffered saline (PBS), and fixed in 70 % etha-
nol at 4 °C overnight. Cells were collected and stained
with propidium iodide (PI). The cell-cycle distributions
were determined by flow cytometry analysis (BD AccuriTM
C6 Flow Cyometer).
Ectopic expression of GLIPR1
Human GLIPR1 cDNA clone (HsCD00441029) in the
lentiviral expression vector pLX304 was purchased from
DNASU (www.dnasu.org/DNASU/Home.do). To in-
crease GLIPR1 expression, three deoxynucleotides
(ACC) were inserted into the GLIPR1 cDNA just before
the initiation codon (ATG). Lentivirus was prepared as
described previously. A549 cells (4 ×104) were plated in
6-well plates and transduced with GLIPR1-expressing
lentivirus or control lentivirus. After 48 h, cells were
replated in 100-mm dish, and 2 days later GLIPR1 ex-
pression was confirmed by Western Blotting analysis.
Lung orthotopic tumors
Six-week-old nude mice were purchased from the Na-
tional Cancer Institute and maintained in a barred ani-
mal facility. Cells injection into mouse lung was
performed as described previously. Mice were killed
21 days after tumor cell injection. The lungs of the mice
were then removed, fixed with formaldehyde, and em-
bedded in paraffin. Paraffin-embedded lung tissue sec-
tions (4 μm) were stained with H&E and evaluated for
tumors. Mice were handled in accordance with the
guidelines published in the National Institutes of Health
Guide for the Care and Use of Laboratory Animals. The
Morehouse Medical School Institutional Animal Care
and Use Committee approved all the experimental
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procedures used for mice. The tumor areas in lungs
were quantified using the ImageJ software program.
Statistical analysis
Data are presented as the means of three independent
experiments ± the standard error of the mean (SEM). A
2-tailed unpaired Student t-test was used to determine
whether differences between control and experiment
samples were statistically significant. P values less than
0.05 were considered statistically significant.
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